| Code | CSB-RA004936MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to dacetuzumab, targeting CD40, a member of the tumor necrosis factor receptor superfamily. CD40 is a transmembrane protein expressed on antigen-presenting cells, B lymphocytes, and various cancer cells, playing a crucial role in immune regulation and cell survival. Upon binding with its ligand CD40L, CD40 initiates signaling cascades that regulate B cell activation, immunoglobulin class switching, and germinal center formation. Dysregulated CD40 signaling is implicated in autoimmune disorders, inflammatory conditions, and hematological malignancies, particularly B cell lymphomas and multiple myeloma.
Dacetuzumab, the reference antibody, is a humanized IgG1 monoclonal antibody that was investigated in clinical trials for hematologic cancers due to its ability to induce growth inhibition and apoptosis in CD40-expressing tumor cells. This biosimilar antibody provides researchers with a valuable tool for investigating CD40-mediated immune responses, exploring therapeutic mechanisms in oncology and immunology, and studying B cell biology and tumor microenvironment interactions in preclinical models.
There are currently no reviews for this product.